NasdaqGS:IMCRBiotechs
How Investors Are Reacting To Immunocore (IMCR) Five-Year KIMMTRAK Survival Data In Uveal Melanoma
Immunocore Holdings plc recently reported five-year overall survival data for KIMMTRAK in unresectable or metastatic uveal melanoma, showing an OS rate of 16% versus 8% for investigator’s choice in the longest prospective Phase 3 randomized trial for this disease.
These results also mark the longest follow-up yet reported for a T cell engager in a solid tumor, highlighting KIMMTRAK’s durable clinical impact in a setting with historically very poor long-term outcomes.
We’ll now examine how...